Mark Bennett

940 total citations
14 papers, 601 citations indexed

About

Mark Bennett is a scholar working on Experimental and Cognitive Psychology, Clinical Psychology and Cognitive Neuroscience. According to data from OpenAlex, Mark Bennett has authored 14 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Experimental and Cognitive Psychology, 5 papers in Clinical Psychology and 3 papers in Cognitive Neuroscience. Recurrent topics in Mark Bennett's work include Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (7 papers), Pharmaceutical studies and practices (2 papers) and Obsessive-Compulsive Spectrum Disorders (2 papers). Mark Bennett is often cited by papers focused on Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (7 papers), Pharmaceutical studies and practices (2 papers) and Obsessive-Compulsive Spectrum Disorders (2 papers). Mark Bennett collaborates with scholars based in Canada, United Kingdom and United States. Mark Bennett's co-authors include Michael Van Ameringen, Catherine Mancini, Loizos Heracleous, Sotirios Paroutis, Beth Patterson, Jonathan M. Oakman, Andrew D. Sumner, Robert Zelis, Pratap Chokka and Joseph A. Gascho and has published in prestigious journals such as The American Journal of Cardiology, Technological Forecasting and Social Change and Drugs.

In The Last Decade

Mark Bennett

14 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Bennett Canada	10	250	147	139	105	83	14	601
Patrick Johnson United States	18	210 0.8×	54 0.4×	60 0.4×	157 1.5×	99 1.2×	57	1.1k
Tapan Parikh United States	10	74 0.3×	19 0.1×	7 0.1×	31 0.3×	40 0.5×	30	379
Hendrik Müller Germany	10	58 0.2×	31 0.2×	4 0.0×	104 1.0×	58 0.7×	29	448
Jun Ren China	13	112 0.4×	80 0.5×	8 0.1×	45 0.4×	88 1.1×	41	466
Chang Xi China	12	110 0.4×	117 0.8×	2 0.0×	107 1.0×	196 2.4×	28	465
Alexandra Economou Greece	17	74 0.3×	92 0.6×	7 0.1×	238 2.3×	317 3.8×	56	1.2k
Kevin McSorley United Kingdom	10	20 0.1×	65 0.4×	6 0.0×	56 0.5×	94 1.1×	16	470
Nicole Kraemer Germany	6	40 0.2×	75 0.5×	6 0.0×	53 0.5×	266 3.2×	6	662
Kuan-Yi Wu Taiwan	10	68 0.3×	48 0.3×	5 0.0×	150 1.4×	75 0.9×	22	580
DanaKai Bradford Australia	16	29 0.1×	21 0.1×	6 0.0×	21 0.2×	58 0.7×	38	660

Countries citing papers authored by Mark Bennett

Since Specialization

Citations

This map shows the geographic impact of Mark Bennett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Bennett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Bennett more than expected).

Fields of papers citing papers by Mark Bennett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Bennett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Bennett. The network helps show where Mark Bennett may publish in the future.

Co-authorship network of co-authors of Mark Bennett

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Bennett. A scholar is included among the top collaborators of Mark Bennett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Bennett. Mark Bennett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Shams, Kave, et al.. (2023). P97 Risankizumab real-world effectiveness in UK clinical practice: results from the BADBIR registry. British Journal of Dermatology. 188(Supplement_4). 1 indexed citations

Paroutis, Sotirios, Mark Bennett, & Loizos Heracleous. (2013). A strategic view on smart city technology: The case of IBM Smarter Cities during a recession. Technological Forecasting and Social Change. 89. 262–272. 175 indexed citations

Ameringen, Michael Van, et al.. (2010). The Prevalence of Migraine Headaches in an Anxiety Disorders Clinic Sample. CNS Neuroscience & Therapeutics. 16(2). 76–82. 29 indexed citations

Ameringen, Michael Van, Catherine Mancini, Beth Patterson, Mark Bennett, & Jonathan M. Oakman. (2010). A Randomized, Double-Blind, Placebo-Controlled Trial of Olanzapine in the Treatment of Trichotillomania. The Journal of Clinical Psychiatry. 71(10). 1336–1343. 85 indexed citations

Ameringen, Michael Van, Catherine Mancini, Jonathan M. Oakman, et al.. (2007). Nefazodone in the Treatment of Generalized Social Phobia. The Journal of Clinical Psychiatry. 68(2). 288–295. 19 indexed citations

Ameringen, Michael Van, Catherine Mancini, Beth Patterson, & Mark Bennett. (2007). Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series. Journal of Psychopharmacology. 21(5). 472–476. 26 indexed citations

Ameringen, Michael Van, Catherine Mancini, Beth Patterson, & Mark Bennett. (2005). An evaluation of paroxetine in generalised social anxiety disorder. Expert Opinion on Pharmacotherapy. 6(5). 819–830. 3 indexed citations

Mancini, Catherine, et al.. (2005). Emerging Treatments for Child and Adolescent Social Phobia: AReview. Journal of Child and Adolescent Psychopharmacology. 15(4). 589–607. 38 indexed citations

Ameringen, Michael Van, Catherine Mancini, Beth Patterson, & Mark Bennett. (2005). Topiramate augmentation in treatment-resistant obsessive–compulsive disorder: a retrospective, open-label case series. Depression and Anxiety. 23(1). 1–5. 72 indexed citations

10.

Ameringen, Michael Van, et al.. (2004). Optimizing Treatment in Social Phobia: A Review of Treatment Resistance. CNS Spectrums. 9(10). 753–762. 35 indexed citations

11.

Ameringen, Michael Van, et al.. (2004). Antiepileptic Drugs in the Treatment of Anxiety Disorders. Drugs. 64(19). 2199–2220. 53 indexed citations

12.

Ameringen, Michael Van, et al.. (2004). An Open Trial of Topiramate in the Treatment of Generalized Social Phobia. The Journal of Clinical Psychiatry. 65(12). 1674–1678. 54 indexed citations

13.

Bennett, Mark, et al.. (1989). Self‐disclosure in a clinical context by Asian and British psychiatric out‐patients*. British Journal of Clinical Psychology. 28(2). 155–163. 5 indexed citations

14.

Sumner, Andrew D., Robert Zelis, Mark Bennett, & Joseph A. Gascho. (1989). Effect of the venodilated state on sympathetic-induced venoconstriction in normal subjects. The American Journal of Cardiology. 63(13). 973–976. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact